Frequency of Platelet type versus Type 2B von Willebrand Disease

Alexander Hamilton; Margareth Ozelo; Jayne Leggo; Colleen Notley; Hannah Brown; Juan Pablo Frontroth; Anne Angelillo-Scherrer; Fariba Baghaei; Said M. Enayat; Emmanuel Favaloro; David Lillicrap; Maha Othman

doi:10.1160/TH10-08-0523

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(03): 501-508
DOI: 10.1160/TH10-08-0523

Platelets and Blood Cells

Schattauer GmbH

Frequency of Platelet type versus Type 2B von Willebrand Disease

An international registry-based study

Authors

Alexander Hamilton

¹Laurentian University- St Lawrence College Collaborative Program, Kingston, Ontario, Canada
Margareth Ozelo

²Hemocentro UNICAMP, State University of Campinas, Brazil
Jayne Leggo

³Pathology and Molecular Medicine, Queen’s university, Kingston, Ontario, Canada
Colleen Notley

³Pathology and Molecular Medicine, Queen’s university, Kingston, Ontario, Canada
Hannah Brown

³Pathology and Molecular Medicine, Queen’s university, Kingston, Ontario, Canada
Juan Pablo Frontroth

⁴Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Servicio de Hematología/Oncología, Argentina
Anne Angelillo-Scherrer

⁵Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire, Vaudois and University of Lausanne, Lausanne, Switzerland
Fariba Baghaei

⁶Department of Hematology and Coagulation, Sahlgrenska University Hospital, Sweden
Said M. Enayat

⁷Department of Haematology, The Birmingham Children’s Hospital, Birmingham, UK
Emmanuel Favaloro

⁸Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, New South Wales, Australia
David Lillicrap

³Pathology and Molecular Medicine, Queen’s university, Kingston, Ontario, Canada
Maha Othman

¹Laurentian University- St Lawrence College Collaborative Program, Kingston, Ontario, Canada

⁹Department of Anatomy and Cell Biology, Queen’s University, Kingston, Ontario, Canada

Abstract

Summary

Less than 50 patients are reported with platelet type von Willebrand disease (PT-VWD) worldwide. Several reports have discussed the diagnostic challenge of this disease versus the closely similar disorder type 2B VWD. However, no systematic study has evaluated this dilemma globally. Over three years, a total of 110 samples/data from eight countries were analysed. A molecular approach was utilised, analysing exon 28 of the von Willebrand factor (VWF) gene, and in mutation negative cases the platelet GP1BA gene. Our results show that 48 cases initially diagnosed as putative type 2B/PT-VWD carried exon 28 mutations consistent with type 2B VWD, 17 carried GP1BA mutations consistent with a PT-VWD diagnosis, three had other VWD types (2A and 2M) and five expressed three non-previously published exon 28 mutations. Excluding 10 unaffected family members and one acquired VWD, 26 cases did not have mutations in either genes. Based on our study, the percentage of type 2B VWD diagnosis is 44% while the percentage of misdiagnosis of PT-VWD is 15%. This is the first large international study to investigate the occurrence of PT-VWD and type 2B VWD worldwide and to evaluate DNA analysis as a diagnostic tool for a large cohort of patients. The study highlights the diagnostic limitations due to unavailability/poor application of RIPA and related tests in some centres and proposes genetic analysis as a suitable tool for the discrimination of the two disorders worldwide. Cases that are negative for both VWF and GP1BA gene mutations require further evaluation for alternative diagnoses.

Keywords

VWF- A1 domain - platelets - RIPA - VWF multimers - type 2B VWD - GP1BA - rare bleeding disorders - platelet function defect

Full Text

References

References
1 Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775-777.
2 Titani K, Kumar S, Takio K. et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-3184.
3 Mancuso DJ, Tuley EA, Westfield LA. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
4 Federici AB, Mannucci PM, Stabile F. et al. A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype. Thromb Haemost 1997; 78: 1132-1137.
5 Casonato A, Sartorello F, Pontara E. et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive pheno-type and a difficult diagnosis. Thromb Haemost 2007; 98: 1182-1187.
6 Baronciani L, Federici AB, Beretta M. et al. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3: 2689-2694.
7 Takimoto Y, Imanaka F. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Wille-brand factor multimers in plasma. Int J Hematol 1999; 70: 127-131.
8 Poon MC, Rand ML, Jackson SC. 2B or not to be – The 45-year saga of the Montreal Platelet Syndrome. Thromb Haemost 2010; 104: 903-910.
9 Weiss HJ, Meyer D, Rabinowitz R. et al. Pseudo-von Willebrand‘s disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 30: 326-333.
10 Miller JL, Castella A. Platelet-type von Willebrand‘s disease: characterization of a new bleeding disorder. Blood 1982; 60: 790-794.
11 Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996; 75: 865-869.
12 Favaloro EJ, Bonar R, Meiring M. et al. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98: 346-358.
13 Whalley IN, Perry DJ. 2B or not 2B? Differential identification of Type 2B, versus pseudo-,von Willebrand disease. Br J Haematol 2007; 136: 345 author reply –346.
14 Othman M, Lillicrap D. Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease. Br J Haematol 2007; 138: 665-666.
15 Enayat MS, Guilliatt AM, Lester W. et al. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol 2006; 133: 664-666.
16 Mathew P, Greist A, Maahs JA. et al. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 2003; 9: 137-144.
17 Saba HI, Saba SR, Dent J. et al. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation. Blood 1985; 66: 282-286.
18 Olson JD, Preston FE, Nichols WL. External quality assurance in thrombosis and hemostasis: an international perspective. Semin Thromb Hemost 2007; 33: 220-225.
19 Othman MLJ, Notley C, James P. et al. Platelet Type von Willebrand disease: an under diagnosed cause of excessive mucocutanous bleeding. J Thromb Haemost. 2007 5 (Suppl. 1): Abstract P-W-167.
20 Othman M, Ozelo M, Brown H. et al. Canadian Platelet-type von Willebrand disease (PT-VWD) project: Progress and update. J Thromb Haemost. 2009 7 (Suppl. 2): Abstract OC-WE-134.
21 Othman M, Hamilton A. Platelet-type von Willebrand disease: results of a worldwide survey from the Canadian PT-VWD project. Acta Haematol 2010; 123: 126-128.
22 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
23 Othman M, Notley C, Lavender FL. et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105: 4330-4336.
24 Favaloro EJ. 2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. Br J Haematol 2006; 135: 141-142 author reply –143.
25 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B?. A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008; 34: 113-127.
26 Frontroth JP, Hepner M, Sciuccati G. et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010; 104: 1158-1165.
27 Favaloro EJ, Patterson D, Denholm A. et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139: 623-626.
28 Scepansky E, Othman M, Smith H. Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas. J Thromb Haemost. 2009 5 (Suppl. 1): Abstract PP-MO-632.
29 Chegeni R, Vickars L, Favaloro EJ. et al. Functional analysis of three recombinant A1 -VWF domain mutants in comparison to wild type and plasma- derived VWF facilitates subtyping in type 2 von Willebrand disease. Thromb Res. 2010 published online.
30 Othman M. Differential identification of PT-VWD from type 2B VWD and GP1BA nomenclature issues. Br J Haematol 2008; 142: 312-314 author reply 314–315.
31 Facey DA, Favaloro EJ, Maxwell E. et al. Type 2B von Willebrand‘s disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations. Am J Hematol 2000; 63: 197-199.
32 Favaloro EJ, Koutts J, Brighton T. et al. Genetic testing for the diagnosis of von Willebrand Disease: benefits and limitations. J Coagul Dis 2010; 2: 37-47.
33 Corrales I, Ramirez L, Altisent C. et al. Rapid molecular diagnosis of von Wille-brand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101: 570-576.
34 James P, Lillicrap D. The role of molecular genetics in diagnosing von Willebrand disease. Semin Thromb Hemost 2008; 34: 502-508.
35 Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: ″true 2B″, ″tricky 2B″, or ″not 2B″. What are the modifiers of the phenotype? Semin Thromb Hemost 2008; 34: 520-531.
36 Federici AB, Mannucci PM, Castaman G. et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526-534.
37 Lopez-Fernandez MF, Lopez-Berges C, Martin-Bernal JA. et al. Type IIB von Willebrand‘s disease associated with a complex thrombocytopenic thrombocytopathy. Am J Hematol 1988; 27: 291-298.
38 Nurden P, Debili N, Vainchenker W. et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 2006; 108: 2587-2595.
39 Nurden P, Chretien F, Poujol C. et al. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol 2000; 110: 704-714.
40 Nurden AT, Federici AB, Nurden P. Altered megakaryocytopoiesis in von Wille-brand type 2B disease. J Thromb Haemost 2009; 7 (Suppl. 01) 277-281.
41 Nurden P, Gobbi G, Nurden A. et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115: 2649-2656.
42 Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313-317.
43 Novelli EM, Ragni MV. Genetics of bleeding disorders in women. Semin Thromb Hemost 2008; 34: 509-519.